2010
DOI: 10.1002/pros.21292
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: Background-The peroxiredoxins (PRDXs) are emerging as regulators of antioxidant defense, apoptosis, and therapy resistance in cancer. Because their significance in prostate cancer (PCa) is unclear, we investigated their expression and clinical associations in PCa.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

6
74
0

Year Published

2011
2011
2021
2021

Publication Types

Select...
9

Relationship

2
7

Authors

Journals

citations
Cited by 72 publications
(80 citation statements)
references
References 38 publications
(63 reference statements)
6
74
0
Order By: Relevance
“…PRDX3 is an important cellular antioxidant that regulates physiological levels of H 2 O 2 stress to protect cells against apoptosis induced by high levels of H 2 O 2 (25). Basu et al (26) have shown that PRDX3 is overexpressed in prostate cancer and could be a potential biological determinant of health disparities of patients and novel therapeutic targets. Furthermore, downregulation of PRDX3 could be a possible apoptotic pathway for PP2-induced apoptosis in breast cancer of MCF-7 cells (27).…”
Section: Discussionmentioning
confidence: 99%
“…PRDX3 is an important cellular antioxidant that regulates physiological levels of H 2 O 2 stress to protect cells against apoptosis induced by high levels of H 2 O 2 (25). Basu et al (26) have shown that PRDX3 is overexpressed in prostate cancer and could be a potential biological determinant of health disparities of patients and novel therapeutic targets. Furthermore, downregulation of PRDX3 could be a possible apoptotic pathway for PP2-induced apoptosis in breast cancer of MCF-7 cells (27).…”
Section: Discussionmentioning
confidence: 99%
“…As an active responder to oxidative stress, PRX3 (or together with PRX5, another mitochondrial PRX gene) was significantly up-regulated in most common malignancies including breast cancer (Noh et al 2001;Karihtala et al 2003;Chua et al 2010), hepatocellular carcinoma (Choi et al 2002;Qiao et al 2012), malignant mesothelioma (MM) (Kinnula et al 2002), lung cancer Park et al 2006), cervical cancer (Kim et al 2009;Hu et al 2013), colorectal neoplasm (Wu et al 2010), prostate cancer (Basu et al 2011;Whitaker et al 2013), and endometrial cancer .…”
Section: The Expression Of Prx3 and Its Involvement In Apoptosis Of Cmentioning
confidence: 97%
“…PRDX1 overexpression is also found in human prostate cancer specimens and prostate cancer cell lines 17, 100. Prostate cancer risk and prognosis are adversely associated with a number of inflammatory and angiogenic mediators, including Toll‐like receptor 4 (TLR4), NF‐κB and VEGF 101, 102, 103, 104.…”
Section: Prdx1 and Prostate Cancermentioning
confidence: 99%